Clinical Trials Logo

Filter by:
NCT ID: NCT04328935 Active, not recruiting - Clinical trials for Post Traumatic Stress Disorder

Written Exposure Therapy for Post-traumatic Stress Syndrome

Start date: October 27, 2020
Phase: N/A
Study type: Interventional

To investigate if written exposure therapy is feasible for patients with post-traumatic stress disorder

NCT ID: NCT04324840 Active, not recruiting - Glioblastoma Clinical Trials

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Start date: July 10, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of CC-90010 when combined with standard of care treatment, temozolomide (TMZ) with or without radiotherapy (RT) in the newly diagnosed WHO Grade IV glioblastoma (ndGBM).

NCT ID: NCT04317144 Active, not recruiting - Clinical trials for Post Intensive Care Unit Syndrome

Web-based Follow-up to Former ICU Patients

WIVA
Start date: January 7, 2019
Phase: N/A
Study type: Interventional

This study evaluates if a web-based 1-year programme is a useful method for follow-up intensive care survivors with short ICU-stay. Half of the participants are randomized into receiving the web-based follow-up while the other half will receive no follow-up.

NCT ID: NCT04305002 Active, not recruiting - Parkinson Disease Clinical Trials

Exenatide Treatment in Parkinson's Disease

Start date: January 21, 2020
Phase: Phase 2
Study type: Interventional

The development of a disease-modifying therapy that delays, reverses or stops the symptom progression remains the most important unmet goal in the treatment of Parkinson's disease (PD). Apart from its glucose lowering effect, glucagon-like peptide-1 (GLP-1) receptor stimulation has been investigated in animal models of PD and shown to increase neurogenesis, to arrest and possible reverse nigrostriatal damage, and to protect dopaminergic neurons from neurodegeneration. Exenatide is a synthetic analogue of human GLP-1, resistant to the metabolic processes that degrade it in its naturally occurring form. Results from a recent randomised, double-blind, placebo-controlled trial in PD showed that patients in active treatment for one year were improved compared to the placebo arm with regard to their performance in Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale in the practically defined OFF medication state. The aim of this trial is to investigate the effect of Exenatide, 2 mg, subcutaneous injection, once weekly on disease progression represented by the change in longitudinal Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose (FDG-PET) in individual PD subjects, and to identify an Exenatide-related pattern in FDG-PET that will provide insight into the treatment-effect in the brain. The investigators chose the standard regimen prescribed in Type 2 Diabetes Mellitus (T2DM) and the regimen used in a recent trial in PD. The treatment period will be 18 months, and patients will be randomly assigned to either active treatment or placebo. Patients with PD diagnosis, stable on medication during the last year, and Hoehn and Yahr stage 2 or less will be evaluated for the inclusion.

NCT ID: NCT04303780 Active, not recruiting - Clinical trials for KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Start date: June 4, 2020
Phase: Phase 3
Study type: Interventional

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

NCT ID: NCT04300244 Active, not recruiting - Cancer Clinical Trials

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

NIPU
Start date: May 4, 2020
Phase: Phase 2
Study type: Interventional

The objective of the study is to induce a meaningful progression-free survival benefit in patients with Malign Pleural Mesothelioma (MPM) after progression on first line standard platinum doublet chemotherapy, by treating with nivolumab and ipilimumab with or without UV1 vaccine.

NCT ID: NCT04293523 Active, not recruiting - Hemophilia A Clinical Trials

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

A-MORE
Start date: March 30, 2020
Phase:
Study type: Observational

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

NCT ID: NCT04293146 Active, not recruiting - Clinical trials for Breast Reconstruction

Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC

OPBC-02PREPEC
Start date: July 28, 2020
Phase: N/A
Study type: Interventional

This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.

NCT ID: NCT04287621 Active, not recruiting - Asthma Clinical Trials

Registry of Asthma Patients Initiating DUPIXENT®

RAPID
Start date: March 2, 2020
Phase:
Study type: Observational [Patient Registry]

The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: - Patient demographics (eg, gender, age, and race) - Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: - To characterize real-world use patterns of DUPIXENT® for asthma - To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting - To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® - To collect long-term safety data on study participants in the real-world setting

NCT ID: NCT04282785 Active, not recruiting - Sepsis Clinical Trials

Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy

Start date: April 26, 2019
Phase:
Study type: Observational

This prospective clinical study will investigate if antibiotic concentrations in patients with severe infections can be monitored by the UV-VIS spectroscopy.